Valion Bio outlines three-part strategy under new interim CEO

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/21/2026

1. SPCX
2. NVDA
3. NFLX
4. ISRG
5. SMCI
6. GOOGL
7. RTX
8. COF
9. TSLA
10. USO

Go back to Valion Bio outlines three-part strategy under new interim CEO

Valion Bio's New Leadership Unveils 30-Day Agenda to Accelerate Clinical Pipeline and Unlock Shareholder Value

October 21, 2026 8:01 AM EDT

SAN ANTONIO, TX / ACCESS Newswire / October 21, 2026 / Valion Bio, Inc. (NASDAQ: VBIO) ("Valion" or the "Company"), a clinical-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation, today shared the initial findings and priorities from Dean Zikria's first 30 days as Interim Chief Executive Officer. Mr. Zikria's strategic review has set a focused agenda built on three priorities:

Advancing the development of Entolimod and other pipeline assets;Pursuing customer and revenue capabilities for Velocity Bioworks ("Velocity"), the Company's wholly owned... More